Retinal imaging is the best and fastest way to non-invasively detect diabetic retinopathy (DR).
Early detection through retinal screening can prevent 95% of vision loss caused by DR
With 1 in 3 adults with diabetes affected by retinopathy, manual screening methods can no longer keep pace
Eyenuk’s AI identifies critical findings without typically needing patient dilation
Detect more than mild and vision-threatening diabetic retinopathy in seconds with a non-invasive retinal exam.
Autonomous exams at the point of care
No specialist required
Accurate results, delivered in seconds
Built for primary care, endocrinology, optometry, ophthalmology, and more
First and only FDA-cleared AI for vtDR detection
Security compliance with GDPR, SOC 2 Type 2, and HIPAA
Compatible with multiple cameras
Available globally
See what EyeArt can do.
From non-invasive retinal exams to clinical action, the Eyenuk solution provides insights without a trace of burden on the system.
See our full-spectrum solution.
.avif)
Eyenuk has created a system that helps drive an equitable future for healthcare.
Deliver actionable diagnostic reports in under 30 seconds to enable immediate clinical consultation and care planning
Minimize administrative burden with seamless EHR integration that automatically pulls orders from and syncs diagnostic reports to a patient’s medical record
Monitor program performance with on-demand analytics to track screening volumes and pathology trends across all clinical locations
Maximize staff utility by enabling medical assistants to facilitate autonomous screenings, allowing specialists to focus exclusively on complex pathology and interventional treatment
Maximize value-based care bonuses and CMS Star Ratings by closing HEDIS diabetic eye exam gaps during routine primary care visits
Generate immediate revenue at the point of care by billing CPT 92229 for autonomous, specialist-free AI retinal screening
Improve Risk Adjustment Factor (RAF) scores by providing the autonomous diagnostic evidence required to accurately document and code for disease severity
Mitigate the devastating personal and system-wide costs of blindness by preserving patient independence through proactive, AI-enabled detection
Deploy the industry’s first and only FDA-cleared autonomous AI to simultaneously screen for both mtmDR and vtDR
Minimize the “ungradable” bottleneck with real-time image quality feedback that achieves conclusive results for 90%+ patients without dilation and 99% with a small fraction dilated
Future-proof care with a multidisease platform expanding to detect AMD, glaucoma, and predictive biomarkers for systemic cardiovascular and neurological health
Experience the flexibility of an autonomous AI platform cleared for multi-vendor camera integration, supporting your choice of leading retinal imaging hardware
See the proof with your own eyes.
FDA 510(k)-cleared: The only autonomous AI for simultaneous mtmDR and vtDR detection
mtmDR accuracy: 96% sensitivity and 88% specificity for identifying more than mild DR
vtDR accuracy: 97% sensitivity and 90% specificity for identifying vision-threatening disease
Global compliance: EU MDR Class IIb for DR, AMD, and GOND detection
Secure and certified: SOC 2 Type 2, HIPAA, GDPR, and ISO 13485:2016 (MDSAP) compliant for maximum data safety
Camera compatibility: Indicated for use with multiple leading retinal camera manufacturers
View the clinical evidence for yourself.
Our customers see us in a good light, and for good reason.
"Since adopting EyeArt in 2020, we've seen a marked improvement in both efficiency and quality of care. The system has reduced our reliance on manual grading, lowered costs, and simplified our workflows. It enables rapid, reliable screening at the point of care, which has not only made our clinicians' lives easier but has also ensured our patients receive faster, more consistent diagnoses."
"Screening with Eyenuk allows for lower costs to engage patients in primary care instead of making them come see a specialist first. Eyenuk also brings a steady stream of patients who need our help into the specialty practice. We can reduce the number of normal eye exams and improve the odds of matching patients who need our help with the providers who can help them."
"Embedding Eyenuk technology in select primary care clinics has helped us efficiently care for diabetic patients who may not have had access to this important screen. We assess quickly for retinopathy and refer the patient on to our specialty partners as indicated, preventing a delay in care."
"Working with Eyenuk has been a game changer in patient care. EyeArt allows us to quickly and accurately identify early signs of retinal disease in asymptomatic individuals who otherwise might not have sought help. This has enabled earlier intervention, better outcomes, and, in many cases, preserve vision. The ability to bring this level of diagnostic insight into routine diabetes care has truly transformed how we monitor patients’ eye health."
"Through grant funding, we will be able to place Eyenuk cameras in 20 rural primary care locations throughout the state of Nebraska. Meeting patients where they are instead of expecting them to travel will help to ensure diabetic retinopathy screenings are done annually for those that need them."
"We implemented EyeArt in large public screening programs for diabetic retinopathy across the Nordics to support clinical decision-making and optimize specialized resources. Leveraging Eyenuk's scalable infrastructure allowed us to seamlessly and securely integrate AI processing into established workflows."
"We have had very positive experiences with AI-supported diabetic retinopathy screening in our diabetes center. The technology has significantly improved accessibility and efficiency, allowing us to identify patients who require further ophthalmological assessment in a timely manner. In particular, the Eyenuk system has proven to be reliable, easy to integrate into our clinical workflow, and well accepted by both patients and healthcare professionals. We see AI-based retinal screening as an important step towards better prevention and earlier detection of diabetes-related eye disease."
"Vision loss from diabetic retinopathy is preventable, but only if people are screened before symptoms appear. Eyenuk's EyeArt, a Health Canada-approved AI system, removes many of the barriers that keep people from getting checked - reducing wait times for a specialist, minimizing extra time off work, decreasing travel to a clinic that may be hours away. This technology means more people, especially in rural and remote communities across Canada, can be screened where they already receive care. That's not just a cost saving benefit - it's a sight-saving movement."
“EyeArt has been instrumental in helping the Eye Health Screening Initiative bring diabetic retinopathy screening directly into underserved communities. By providing immediate screening results, it supports timely education, referral, and follow-up while allowing limited ophthalmology resources to be focused on those who need them most. Most importantly, it helps us reduce barriers to care for people living in rural, remote, and Indigenous communities.”
"The Eyenuk machine has revolutionized our care for diabetics. It has finally made patients with diabetes, who have refused or been unable to see the need for an Eye Specialist, finally understand the significance of said care. We have saved the vision of multiple patients who did not equate their glucose readings with their eye health. Finally, it has improved the volume of patients receiving diabetic eye screenings in our practice. The patient in his 30s with diabetes that he took for granted for years, who thanked me for finding his retinopathy that has been reversed, is testimony to the benefit of this equipment."
500K+
patients scanned
60K+
patients identified with vision-threatening levels of disease
2MM+
images collected in real-world clinical environments
Start FDA-cleared autonomous diabetic retinopathy screening in your clinic today.
